XML 32 R25.htm IDEA: XBRL DOCUMENT v3.25.3

Revenue (Tables)

9 Months Ended

Sep. 30, 2025

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregated Revenue

The following table presents our disaggregated revenue for the periods presented (in thousands):

		Three Months Ended September 30,								Nine Months Ended September 30,
		2025				2024				2025				2024
MRD revenue
Service revenue		$	50,288			$	32,470			$	133,947			$	92,880
Regulatory milestone revenue			6,500				5,000				16,500				12,500
Total MRD revenue			56,788				37,470				150,447				105,380
Immune Medicine revenue
Service revenue			3,443				5,453				13,566				16,160
Collaboration revenue(1)			33,742				3,512				41,282				9,958
Total Immune Medicine revenue			37,185				8,965				54,848				26,118
Total revenue		$	93,973			$	46,435			$	205,295			$	131,498

(1) On August 13, 2025, the Genentech Agreement was terminated, with termination effective February 9, 2026. See “Genentech Collaboration Agreement” below for more information regarding the resulting impact on revenue recognized during the three and nine months ended September 30, 2025.

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration